
Sign up to save your podcasts
Or


This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025, the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA.
By Sam and Karine4.8
193193 ratings
This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025, the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA.

320 Listeners

500 Listeners

39 Listeners

119 Listeners

58 Listeners

3,376 Listeners

1,150 Listeners

188 Listeners

47 Listeners

516 Listeners

369 Listeners

52 Listeners

58 Listeners

51 Listeners

46 Listeners